Idiopathic pulmonary fibrosis and cancer: Do they really look similar?

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Vancheri, Carlo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Cancer; Idiopathic pulmonary fibrosis; Pathogenesis; Signalling transduction pathways

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; BLEOMYCIN; CIGARETTE SMOKE; CONNEXIN 43; CYCLIN D1; FASCIN; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBRONECTIN; GAP JUNCTION PROTEIN; HEAT SHOCK PROTEIN; JANUS KINASE; LAMININ; MATRILYSIN; METALLOPROTEINASE; MICRORNA; NINTEDANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN P53; SMALL UNTRANSLATED RNA; STAT PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN RECEPTOR; WNT PROTEIN;

AGING; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CLINICAL FEATURE; CYTOSKELETON; DIET; DOWN REGULATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FIBROSING ALVEOLITIS; GENE SILENCING; HUMAN; LUNG ALVEOLUS EPITHELIUM CELL; LUNG CANCER; LUNG CARCINOGENESIS; LUNG FUNCTION; MYOFIBROBLAST; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; TELOMERE SHORTENING; UPREGULATION; WNT SIGNALING PATHWAY; GENETICS; NEOPLASM;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84959921191     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0478-1     Document Type: Article

References (58)

1. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-51.
2. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-9.
3. Haddow A. Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv Cancer Res. 1972;16:181-234.
4. Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, et al. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res. 2006;66:7216-24.
5. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35:496-504.
6. Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev. 2013;22:265-72.
7. Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157-64.
8. Sanders YY, Kumbla P, Hagood JS. Enhanced myofibroblastic differentiation and survival in Thy-1(-) lung fibroblasts. Am J Respir Cell Mol Biol. 2007;36:226-35.
9. Sanders YY, Pardo A, Selman M, Nuovo GJ, Tollefsbol TO, Siegal GP, et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008;39:610-8.
10. Rabinovich EI, Kapetanaki MG, Steinfeld I, Gibson KF, Pandit KV, Yu G, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS One. 2012;7:e33770.
11. Hojo S, Fujita J, Yamadori I, Kamei T, Yoshinouchi T, Ohtsuki Y, et al. Heterogeneous point mutations of the p53 gene in pulmonary fibrosis. Eur Respir J. 1998;12:1404-8.
12. Uematsu K, Yoshimura A, Gemma A, Mochimaru H, Hosoya Y, Kunugi S, et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res. 2001;61:8527-233.
13. Demopoulos K, Arvanitis DA, Vassilakis DA, Siafakas NM, Spandidos DA. MYCL1, FHIT, SPARC, P16(INK4) and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med. 2002;6:215-22.
14. Vassilakis DA, Sourvinos G, Spandidos DA, Siafakas NM, Bouros D. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2000;162:1115-9.
15. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:729-37.
16. De Leon AD, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One. 2010;5:e10680.
17. Antoniou KM, Samara KD, Lasithiotaki I, Margaritopoulos GA, Soufla G, Lambiri I, et al. Differential telomerase expression in idiopathic pulmonary fibrosis and non-small cell lung cancer. Oncolog Rep. 2013;30:2617-24.
18. Ang S, Banerjee S, de Freitas A, Sanders YY, Ding Q, Matalon S, et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol. 2012;180:484-93.
19. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45:287-94.
20. Yamada M, Kubo H, Ota C, Takahashi T, Tando Y, Suzuki T, et al. The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells. Respir Res. 2013;14:95.
21. Pottier N, Maurin T, Chevalier B, Puisségur MP, Lebrigand K, Robbe-Sermesant K, et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibro-blasts: implication in epithelial-mesenchymal interactions. PLoS One. 2009;4:e6718.
22. Oak SR, Murray L, Herath A, Sleeman M, Anderson I, Joshi AD, et al. A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One. 2011;6:e21253.
23. Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;182:220-9.
24. Kojima T, Spray DC, Kokai Y, Chiba H, Mochizuki Y, Sawada N. Cx32 formation and/or Cx32-mediated intercellular communication induces expression and function of tight junctions in hepatocytic cell line. Exp Cell Res. 2002;276:40-51.
25. Koval M, Billaud M, Straub AC, Johnstone SR, Zarbock A, Duling BR, et al. Spontaneous lung dysfunction and fibrosis in mice lacking connexin 40 and endothelial cell connexin 43. Am J Pathol. 2011;178:2536-46.
26. Mori R, Power KT, Wang CM, Martin P, Becker DL. Acute downregulation of connexin43 at wound sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast migration. J Cell Sci. 2006;119:5193-203.
27. Trovato-Salinaro A, Trovato-Salinaro E, Failla M, Mastruzzo C, Tomaselli V, Gili E, et al. Altered intercellular communication in lung fibroblast culture from patients with IPF. Respir Res. 2006;7:122.
28. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc. 2006;3:377-82.
29. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta: potential role in idiopathic pulmonary fibrosis. Am J Pathol. 2005;166:1321-32.
30. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A. 2006;103:13180-5.
31. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 2008;130:481-94.
32. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc. 2006;3:364-72.
33. Andersson-Sjöland A, de Alba CG, Nihlberg K, Becerril C, Ramírez R, Pardo A, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol. 2008;40:2129-40.
34. Dancer RC, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J. 2011;38:1461-7.
35. Niki T, Kohno T, Iba S, Moriya Y, Takahashi Y, Saito M, et al. Frequent colocalization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol. 2002;160:1129-41.
36. Hashimoto Y, Skacel M, Adams JC. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol. 2005;37:1787-804.
37. Chilosi M, Zamò A, Doglioni C, Reghellin D, Lestani M, Montagna L, et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res. 2006;7:95.
38. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett. 2005;222:1-10.
39. Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003;162:1495-502.
40. Caraci F, Gili E, Calafiore M, Failla M, La Rosa C, Crimi N, et al. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblast into myofibroblasts. Pharmacol Res. 2008;57:274-82.
41. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-7.
42. Conte E, Gili E, Fruciano M, Korfei M, Fagone E, Iemmolo M, et al. PI3K p110g overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Lab Invest. 2013;93:566-76.
43. Wei X, Han J, Chen ZZ, Qi BW, Wang GC, Ma YH, et al. A phosphoinositide 3-kinasegamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun. 2010;397:311-7.
44. Bao Z, Zhang Q, Wan H, He P, Zhou X, Zhou M. Expression of suppressor of cytokine signaling 1 in the peripheral blood of patients with idiopathic pulmonary fibrosis. Chin Med J. 2014;127:2117-20.
45. Beyer C, Distler JH. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim Biophys Acta. 2013;1832:897-904.
46. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007;29:976-85.
47. Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllarniemi M. Imatinibmesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res. 2007;33:357-73.
48. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604-10.
49. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;65:1079-87.
50. Brown KKRL, Costabel U, Flaherty KR, Kim D, Noble PW, Raghu G, et al. Treatment of IPF with the tyrosine kinase inhibitor bibf 1120: Patient-reported outcomes in the tomorrow trial. Am J Respir Crit Care Med. 2012;185:A3634.
51. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
52. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92. Erratum in. N Engl J Med. 2014;371(12):1172. doi: 10.1056/NEJMoa1402582.
53. Teixeira MR, Heim S. Cytogenetic analysis of tumor clonality. Adv Cancer Res. 2011;112:127-49.
54. Kotiligam D, Lazar AJ, Pollock RE, Lev D. Desmoid tumor: a disease opportune for molecular insights. Histol Histopathol. 2008;23:117-26.
55. Shah AA, Barfield ME, Kelsey CR, Onaitis MW, Tong B, Harpole D, et al. Outcomes after surgical management of synchronous bilateral primary lung cancers. Cancers Ann Thorac Surg. 2012;93:1055-60.
56. Trousse D, Barlesi F, Loundou A, Tasei AM, Doddoli C, Giudicelli R, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg. 2007;133:1193-200.
57. Kwast AB, Liu L, Roukema JA, Voogd AC, Jobsen JJ, Coebergh JW, et al. Increased risks of third primary cancers of non-breast origin among women with bilateral breast cancer. Br J Cancer. 2012;107(3):549-55.
58. Shuch B, Singer EA, Bratslavsky G. The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin North Am. 2012;39:133-48.